Log in
ETR:BIO

Biotest Aktiengesellschaft (BIO.F) Stock Forecast, Price & News

€26.60
+1.00 (+3.91 %)
(As of 11/24/2020 12:00 AM ET)
Add
Compare
Today's Range
€26.20
Now: €26.60
€26.60
50-Day Range
€25.60
MA: €26.98
€29.20
52-Week Range
€17.20
Now: €26.60
€31.80
Volume972 shs
Average Volume1,927 shs
Market Capitalization$526.30 million
P/E RatioN/A
Dividend Yield0.19%
BetaN/A
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; Zutectra for hepatitis B re-infection prophylaxis after liver transplantation; and Cytotect 70(BT-094) for prevention of cytomegalovirus infection in the foetus during pregnancy with mother's CMV infection. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.
Read More
Biotest Aktiengesellschaft (BIO.F) logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-6103-8010
Employees1,871

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$465.80 million
Cash Flow€1.87 per share
Book Value€11.47 per share

Profitability

Miscellaneous

Market Cap$526.30 million
Next Earnings DateN/A
OptionableOptionable
€26.60
+1.00 (+3.91 %)
(As of 11/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biotest Aktiengesellschaft (BIO.F) (ETR:BIO) Frequently Asked Questions

How has Biotest Aktiengesellschaft (BIO.F)'s stock price been impacted by Coronavirus?

Biotest Aktiengesellschaft (BIO.F)'s stock was trading at €18.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIO stock has increased by 44.6% and is now trading at €26.60.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Biotest Aktiengesellschaft (BIO.F)?

Wall Street analysts have given Biotest Aktiengesellschaft (BIO.F) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biotest Aktiengesellschaft (BIO.F) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Biotest Aktiengesellschaft (BIO.F)'s key competitors?

What other stocks do shareholders of Biotest Aktiengesellschaft (BIO.F) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotest Aktiengesellschaft (BIO.F) investors own include Grifols (GRFS), CSL Limited (CSL.AX) (CSL), BioXcel Therapeutics (BTAI) and ADMA Biologics (ADMA).

Who are Biotest Aktiengesellschaft (BIO.F)'s key executives?

Biotest Aktiengesellschaft (BIO.F)'s management team includes the following people:
  • Dr. Michael Ramroth, Chairman of the Management Board, CEO & CFO (Age 59, Pay $1.11M)
  • Dr. Georg Floß, COO & Member of the Board of Management
  • Dr. Monika Buttkereit, Head of Investor Relations
  • Dr. Christina Erb, Head of Corp. HR
  • Dr. Katrin Bernöster, Head of the Project Management Organisation
  • Mr. Peter Seith, Head of Quality Operations
  • Dr. Jörg Schüttrumpf, Head of R&D
  • Dr. Wolfgang Möller, Head of Devel. - Plasma Protein
  • Dr. Hermann Keuper, Sr. VP of Manufacturing

What is Biotest Aktiengesellschaft (BIO.F)'s stock symbol?

Biotest Aktiengesellschaft (BIO.F) trades on the ETR under the ticker symbol "BIO."

What is Biotest Aktiengesellschaft (BIO.F)'s stock price today?

One share of BIO stock can currently be purchased for approximately €26.60.

How big of a company is Biotest Aktiengesellschaft (BIO.F)?

Biotest Aktiengesellschaft (BIO.F) has a market capitalization of $526.30 million and generates $465.80 million in revenue each year. Biotest Aktiengesellschaft (BIO.F) employs 1,871 workers across the globe.

What is Biotest Aktiengesellschaft (BIO.F)'s official website?

The official website for Biotest Aktiengesellschaft (BIO.F) is www.biotest.com.

How can I contact Biotest Aktiengesellschaft (BIO.F)?

Biotest Aktiengesellschaft (BIO.F)'s mailing address is Landsteinerstr. 5, DREIEICH, 63303, Germany. The company can be reached via phone at +49-6103-8010.

This page was last updated on 11/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.